Telik Reports Positive New TELCYTA Preclinical Data At American Association For Cancer Research Annual Meeting

Telik, Inc.
(Nasdaq: TELK) announced that the presentation today of new preclinical
studies of TELCYTA(R) (canfosfamide HCl, TLK286) that support clinical
evaluation of the triplet combination of TELCYTA, carboplatin and
paclitaxel in the treatment of advanced non-small cell lung and ovarian
cancer. The company also reported studies demonstrating the anti-angiogenic
activity of TELCYTA alone and in combination with bevacizumab. The data
were presented at the 98th annual meeting of the American Association for
Cancer Research (AACR) in Los Angeles.


One series of studies focused on cellular and molecular correlates of
synergistic cancer cell growth inhibition caused by TELCYTA, carboplatin or
paclitaxel alone and in doublet and triplet combinations in human lung
cancer cells. The triplet combination of TELCYTA, carboplatin and
paclitaxel resulted in significantly enhanced cancer cell cycle arrest
compared to the single agents alone or the carboplatin/paclitaxel doublet
combination. Compared to the single agents, the combination of TELCYTA and
paclitaxel increased apoptosis and cell cycle arrest in the cancer cells.
These studies support the positive clinical data from the Phase 2 study of
TELCYTA plus carboplatin and paclitaxel in the first-line treatment of
advanced non-small cell lung cancer, reported earlier today at the AACR
meeting.



A separate series of studies evaluated the anti-angiogenic effects of
TELCYTA with and without bevacizumab, an approved anti-angiogenic agent.
The studies demonstrated that TELCYTA is a potent inhibitor of human
endothelial cell proliferation in vitro. When TELCYTA and bevacizumab were
combined, the inhibitory effects on endothelial cell proliferation and
capillary tubule formation were significantly enhanced. These studies
suggest the potential for TELCYTA use in combination with bevacizumab and
other anti-angiogenic agents.



Telik, Inc. of Palo Alto, CA is a biopharmaceutical company focused on
discovering, developing and commercializing novel small molecule drugs to
treat serious diseases. The company's most advanced drug development
candidate is TELCYTA, a tumor-activated small molecule product candidate in
clinical development for the treatment of advanced ovarian cancer and
non-small cell lung cancer. A second drug development candidate,
TELINTRA(TM) (TLK199), is in clinical development in myelodysplastic
syndrome. Telik's product candidates were discovered using its proprietary
drug discovery technology, TRAP(TM), which enables the rapid and efficient
discovery of small molecule drug candidates. Additional information is
available at telik.



This press release contains "forward-looking" statements, including
statements regarding the potential for TELCYTA to treat one or more types
of cancer. There are important factors that could cause Telik's results to
differ materially from those indicated by these forward-looking statements,
including, among others, that none of Telik's product candidates have been
determined to be safe or effective in humans or been approved for
marketing, clinical trials of Telik's product candidates may take several
years to complete and may not be successful, success in preclinical testing
and early clinical trials does not ensure that later clinical trials will
be successful and interim results of clinical trials do not necessarily
predict final results. Detailed information regarding factors that may
cause actual results to differ materially from the results expressed or
implied by statements in this press release may be found in Telik's
periodic filings with the Securities and Exchange Commission, including the
factors described in the section entitled "Risk Factors" in its annual
report on Form 10-K for the year ended December 31, 2006. Telik does not
undertake any obligation to update forward-looking statements contained in
this press release.



TELIK, the Telik logo, TELCYTA, TELINTRA and TRAP are trademarks or
registered trademarks of Telik, Inc.


Telik, Inc.

telik

Our Recommendations:


•   Buy Liv.52 Caps Without Prescription
•   Order Atripla
•   Spiriva Purchase
•   Order Differin
•   Buy Generic Human Growth Hormone